Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Treatment Intensification Guidelines for T2D

Ann Intern Med; ePub 2018 Sep 4; Roglic, et al

The World Health Organization (WHO) has developed guidelines to provide guidance on selection of medicines for treatment intensification in type 2 diabetes (T2D) and on use of insulin in type 1 and 2 diabetes. The recommendations were formulated by a 12-member guideline development group and are based on high-quality systematic reviews from January 1, 2007 to March 2017. The recommendations include:

  • Give a sulfonylurea to patients with T2D who do not achieve glycemic control with metformin alone or who have contraindications to metformin (strong recommendation, moderate-quality evidence).
  • Introduce human insulin treatment to patients with T2D who do not achieve glycemic control with metformin and/or a sulfonylurea (strong recommendation, very-low-quality evidence).
  • If insulin is unsuitable, a dipeptidyl peptidase-4 (DPP-4) inhibitor, a sodium–glucose cotransporter-2 (SGLT-2) inhibitor, or a thiazolidinedione (TZD) may be added (weak recommendation, very-low-quality evidence).
  • Use human insulin to manage blood glucose in adults with type 1 diabetes and in adults with T2D for whom insulin is indicated (strong recommendation, low-quality evidence).
  • Consider long-acting insulin analogues to manage blood glucose in adults with type 1 or T2D who have frequent severe hypoglycemia with human insulin (weak recommendation, moderate-quality evidence for severe hypoglycemia).

Citation:

Roglic G, Norris SL. Medicines for treatment intensification in type 2 diabetes and type of insulin in type 1 and type 2 diabetes in low-resource settings: Synopsis of the World Health Organization Guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in nonpregnant adults with diabetes mellitus. Ann Intern Med. [Published online ahead of print September 4, 2018]. doi:10.7326/M18-1149.

This Week's Must Reads

Is Obesity Associated With Adverse CV Outcomes?, JAMA Netw Open; 2018 Nov 16; Riaz, et al

BMI & Risk of Postpregnancy T2D in Women with HDP , Diabetes Care; ePub 2018 Nov 19; Timpka, et al

Diabetes Outcomes in Patients by PCPs, NPs, or PAs, Ann Intern Med; ePub 2018 Nov 20; Jackson, et al

Traumatic Exposures & Health Issues in Older Women, JAMA Intern Med; ePub 2018 Nov 19; Gibson, et al

Risk of Opioid Overdose Hospitalizations , J Am Board Fam Med; 2018 Nov-Dec; Peters, et al

Must Reads in Clinical Guidelines

Cholesterol Guidelines Stress Lifetime Approach, Circulation; ePub 2018 Nov 10; Grundy, et al

USPSTF: Screen Adults for Unhealthy Alcohol Use, JAMA; 2018 Nov 13; Curry, et al

Screening for Syphilis Infection in Pregnant Women, JAMA; 2018 Sep 4; US Preventive Services Task Force

Treatment Intensification Guidelines for T2D , Ann Intern Med; ePub 2018 Sep 4; Roglic, et al

Low-Calorie Sweetened Beverages & Cardiometabolic Health, Circulation; ePub 2018 Jul 30; Johnson, et al